Secura Bio Secures $145 Million in Financing Led by Athyrium to Advance Oncology Innovations

VCBeat (WeChat Official Account: vcbeat) has learned that on March 5, U.S. biopharmaceutical company Secura Bio announced the completion of a $145 million financing round, comprising a $55 million equity financing from Secura Bio’s executive team and a $90 million debt financing from healthcare investment firm Athyrium Capital Management. The proceeds will be used to research and develop new oncology therapeutics.

Secura Bio is a comprehensive biopharmaceutical company dedicated to providing innovative therapies for cancer patients. Headquartered in Henderson, Nevada, it operates through offices in the United States and San Diego. Currently, Secura Bio’s primary pharmaceutical product is FARYDAK®.

In the United States, myeloma has become the third most common hematologic malignancy, after lymphoma and leukemia. Myeloma originates from the hematopoietic tissue of the bone marrow; due to its tendency to cause multiple bone lesions, it is also referred to as multiple myeloma, and it predominantly affects men over the age of 40. Currently, myeloma is considered a curable disease, but the cure rate with existing treatments remains extremely low.

FARYDAK®, a prescription drug developed by Secura Bio, offers hope to adult patients with multiple myeloma. When taken in combination with the proteasome inhibitor bortezomib and the anti-inflammatory drug dexamethasone, FARYDAK® can slow the growth of multiple myeloma cells at the DNA level.

Secura Bio’s team members possess at least 23 years of experience in the life sciences sector and have collectively launched more than 20 significant therapeutic products. Previously, team members at Secura Bio gained professional experience at numerous successful life sciences companies that were later acquired or went public through initial public offerings (IPOs), including: Sequus (acquired by Alza/J&J), Praecis (acquired by GSK), Aclara (IPO), Gevo (IPO), Prometheus (acquired by Nestlé Health Science), Agarigen (acquired by Intrexon), and Genoptix (acquired by NeoGenomics).

“We are pleased to partner with Athyrium Capital Management and appreciate their impressive investment track record in the life sciences sector,” said Joseph M. Limber, President and Chief Executive Officer of Secura Bio. “We believe that Athyrium Capital Management will help us confidently build a profitable company based on our oncology therapies.”

“We are pleased to collaborate with the Secura Bio management team to identify and acquire multiple oncology therapeutic assets, driving rapid growth and profitability,” said Jeffrey Ferrell, Managing Partner at Athyrium Capital Management. “We believe Secura Bio is well-positioned in oncology therapeutics to quickly establish a significant market presence.”

Athyrium Capital Management (Athyrium) is a specialized asset management firm established in 2008, with a focus on investing in the global healthcare sector. Athyrium provides advisory services backed by over $3.7 billion in committed capital. The Athyrium team possesses extensive investment experience across various asset classes, including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all segments of the healthcare industry, including biopharmaceuticals, medical devices and products, healthcare services, and health information technology. The team collaborates with company management teams to implement innovative financing solutions for their capital needs.

(Compiled by: Tan Xin)